Enanta Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ENTA)

$81.58 +0.24 (+0.30 %)
(As of 02/20/2018 06:24 AM ET)
Previous Close$81.34
Today's Range$80.35 - $82.96
52-Week Range$27.24 - $95.91
Volume142,600 shs
Average Volume240,739 shs
Market Capitalization$1.56 billion
P/E Ratio42.49
Dividend YieldN/A
Beta1.04

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Debt-to-Equity RatioN/A
Current Ratio12.88%
Quick Ratio12.88%

Price-To-Earnings

Trailing P/E Ratio42.49
Forward P/E Ratio94.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.81 million
Price / Sales15.20
Cash Flow$1.08 per share
Price / Cash75.82
Book Value$15.80 per share
Price / Book5.16

Profitability

Trailing EPS$1.73
Net Income$17.71 million
Net Margins26.35%
Return on Equity13.33%
Return on Assets12.50%

Miscellaneous

Employees89
Outstanding Shares19,160,000

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings data on Monday, November, 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.13 by $0.27. The biotechnology company had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The business's revenue for the quarter was up 491.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) earnings per share. View Enanta Pharmaceuticals' Earnings History.

When will Enanta Pharmaceuticals make its next earnings announcement?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2018?

4 analysts have issued 1-year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $36.00 to $78.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $51.25 in the next twelve months. View Analyst Ratings for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:

  • Bruce L.A. Carter Ph.D., Independent Chairman of the Board (Age 74)
  • Jay R. Luly Ph.D., President, Chief Executive Officer, Director (Age 61)
  • Paul J. Mellett Jr., Chief Financial Officer, Senior Vice President - Finance & Administration (Age 62)
  • Yat Sun Or Ph.D., Senior Vice President - Research & Development, Chief Scientific Officer (Age 65)
  • Nathaniel S. Gardiner J.D., Senior Vice President, General Counsel (Age 63)
  • Nathalie Adda M.D., Senior Vice President and Chief Medical Officer (Age 52)
  • Timothy D. Ocain Ph.D., Senior Vice President - New Product Strategy and Development (Age 60)
  • Stephen Buckley Jr., Independent Director (Age 68)
  • George S. Golumbeski Ph.D., Independent Director (Age 60)
  • Kristine Peterson, Independent Director (Age 58)

Who owns Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.24%), First Manhattan Co. (5.67%), Farallon Capital Management LLC (4.83%), Renaissance Technologies LLC (4.03%), Franklin Resources Inc. (1.66%) and Millennium Management LLC (1.15%). Company insiders that own Enanta Pharmaceuticals stock include Nathaniel S Gardiner and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Candriam Luxembourg S.C.A., Armistice Capital LLC, Alliancebernstein L.P., Dupont Capital Management Corp, Adams Diversified Equity Fund Inc., Bank of New York Mellon Corp and Metropolitan Life Insurance Co. NY. View Insider Buying and Selling for Enanta Pharmaceuticals.

Who bought Enanta Pharmaceuticals stock? Who is buying Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Millennium Management LLC, First Manhattan Co., Franklin Resources Inc., BlackRock Inc., Renaissance Technologies LLC, Two Sigma Investments LP and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy Enanta Pharmaceuticals stock?

Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $81.58.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.56 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $1.73 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (ENTA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enanta Pharmaceuticals (NASDAQ:ENTA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.252.502.752.67
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.25$45.25$46.25$38.00
Price Target Upside: 42.45% downside22.89% downside6.96% downside3.43% downside

Enanta Pharmaceuticals (NASDAQ:ENTA) Consensus Price Target History

Price Target History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Royal Bank of CanadaBoost Price TargetSector Perform$78.00HighView Rating Details
2/8/2018JPMorgan Chase & Co.DowngradeOverweight -> NeutralHighView Rating Details
10/4/2017JMP SecuritiesBoost Price Target$40.00 -> $53.00LowView Rating Details
8/8/2017Robert W. BairdBoost Price TargetNeutral$27.00 -> $36.00MediumView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Enanta Pharmaceuticals (NASDAQ:ENTA) Earnings History and Estimates Chart

Earnings by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ ENTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.37)N/AView Earnings Details
11/20/2017Q4 2017$2.13$1.86$73.80 million$75.93 millionViewN/AView Earnings Details
8/7/2017Q3 2017($0.49)($0.44)$8.08 million$7.51 millionViewListenView Earnings Details
5/8/2017Q2 2017($0.38)($0.28)$9.19 million$9.00 millionViewListenView Earnings Details
2/8/2017Q117($0.18)($0.26)$12.70 million$11.90 millionViewListenView Earnings Details
11/21/2016Q416($0.11)($0.09)$13.56 million$12.80 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.06)$13.07 million$14.00 millionViewListenView Earnings Details
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details
8/11/2014Q314$1.65$1.81$40.83 million$42.10 millionViewN/AView Earnings Details
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details
5/8/2013Q2 2013$1.45($2.28)$11.00 million$1.20 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Enanta Pharmaceuticals (NASDAQ:ENTA) Earnings Estimates

Current Year EPS Consensus Estimate: $0.86 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS

Dividends

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.56%
Institutional Ownership Percentage: 67.70%
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2017Yat Sun OrInsiderSell13,921$35.09$488,487.89301,876View SEC Filing  
11/29/2016Yat Sun OrInsiderSell13,921$31.44$437,676.24315,797View SEC Filing  
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.001,900View SEC Filing  
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.0015,295View SEC Filing  
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.0054,397View SEC Filing  
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.0060,397View SEC Filing  
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.0067,897View SEC Filing  
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00184,078View SEC Filing  
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00544,338View SEC Filing  
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00189,078View SEC Filing  
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00199,078View SEC Filing  
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00569,338View SEC Filing  
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Enanta Pharmaceuticals (NASDAQ ENTA) News Headlines

Source:
DateHeadline
Enanta Pharmaceuticals Inc (ENTA) Expected to Post Earnings of $0.10 Per ShareEnanta Pharmaceuticals Inc (ENTA) Expected to Post Earnings of $0.10 Per Share
www.americanbankingnews.com - February 19 at 7:20 PM
Enanta Pharmaceuticals (ENTA) Upgraded to Buy at Zacks Investment ResearchEnanta Pharmaceuticals (ENTA) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - February 12 at 11:18 PM
Enanta Pharmaceuticals to Present at Two Upcoming Investor ConferencesEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 12 at 9:26 AM
Enanta Pharmaceuticals (ENTA) Rating Lowered to Neutral at JPMorgan Chase & Co.Enanta Pharmaceuticals (ENTA) Rating Lowered to Neutral at JPMorgan Chase & Co.
www.americanbankingnews.com - February 11 at 2:12 PM
Enanta Pharmaceuticals (ENTA) PT Raised to $78.00 at Royal Bank of CanadaEnanta Pharmaceuticals (ENTA) PT Raised to $78.00 at Royal Bank of Canada
www.americanbankingnews.com - February 11 at 1:06 PM
Enanta Pharmaceuticals (ENTA) Lowered to "Buy" at BidaskClubEnanta Pharmaceuticals (ENTA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - February 10 at 11:40 AM
Should You Sell Enanta Pharmaceuticals Inc (NASDAQ:ENTA) At This PE Ratio?Should You Sell Enanta Pharmaceuticals Inc (NASDAQ:ENTA) At This PE Ratio?
finance.yahoo.com - February 8 at 4:07 PM
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
finance.yahoo.com - February 8 at 8:38 AM
Enanta Pharmaceuticals posts 1Q profitEnanta Pharmaceuticals posts 1Q profit
finance.yahoo.com - February 8 at 8:38 AM
 Brokerages Expect Enanta Pharmaceuticals Inc (ENTA) to Announce $0.05 EPS Brokerages Expect Enanta Pharmaceuticals Inc (ENTA) to Announce $0.05 EPS
www.americanbankingnews.com - February 2 at 7:10 PM
Enanta Pharmaceuticals (ENTA) Lowered to Sell at Zacks Investment ResearchEnanta Pharmaceuticals (ENTA) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 30 at 10:48 PM
Enanta Pharmaceuticals (ENTA) Set to Announce Quarterly Earnings on TuesdayEnanta Pharmaceuticals (ENTA) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 4:08 AM
Enanta Pharmaceuticals Inc (ENTA) Receives Average Rating of "Hold" from AnalystsEnanta Pharmaceuticals Inc (ENTA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 11:56 AM
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2017Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2017
finance.yahoo.com - January 24 at 9:58 AM
Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $27.26 MillionEnanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $27.26 Million
www.americanbankingnews.com - January 18 at 2:38 AM
Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Earnings of $0.05 Per ShareEnanta Pharmaceuticals Inc (ENTA) Expected to Announce Earnings of $0.05 Per Share
www.americanbankingnews.com - January 16 at 9:24 PM
Enanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of JP Morgan Healthcare ... - StreetInsider.comEnanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of JP Morgan Healthcare ... - StreetInsider.com
www.streetinsider.com - January 7 at 5:32 PM
Enanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of J.P. Morgan Healthcare ConferenceEnanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of J.P. Morgan Healthcare Conference
www.streetinsider.com - January 6 at 9:39 AM
$27.26 Million in Sales Expected for Enanta Pharmaceuticals Inc (ENTA) This Quarter$27.26 Million in Sales Expected for Enanta Pharmaceuticals Inc (ENTA) This Quarter
www.americanbankingnews.com - January 2 at 8:10 PM
Enanta Pharmaceuticals Inc (ENTA) Given Average Rating of "Hold" by BrokeragesEnanta Pharmaceuticals Inc (ENTA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 2 at 12:22 PM
Why Enanta Pharmaceuticals Inc (NASDAQ:ENTA) May Not Be As Efficient As Its IndustryWhy Enanta Pharmaceuticals Inc (NASDAQ:ENTA) May Not Be As Efficient As Its Industry
finance.yahoo.com - January 2 at 9:35 AM
Biohaven Pharmaceutical (BHVN) vs. Enanta Pharmaceuticals (ENTA) Financial SurveyBiohaven Pharmaceutical (BHVN) vs. Enanta Pharmaceuticals (ENTA) Financial Survey
www.americanbankingnews.com - December 31 at 5:30 PM
Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q4, 2017 By the Numbers : December 27, 2017Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q4, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 9:03 AM
ETFs with exposure to Enanta Pharmaceuticals, Inc. : December 25, 2017ETFs with exposure to Enanta Pharmaceuticals, Inc. : December 25, 2017
finance.yahoo.com - December 25 at 6:58 PM
Enanta Pharmaceuticals Announces Data Presentations at the 2018 NASH-TAG ConferenceEnanta Pharmaceuticals Announces Data Presentations at the 2018 NASH-TAG Conference
finance.yahoo.com - December 21 at 9:40 AM
TheStreet Upgrades Enanta Pharmaceuticals (ENTA) to B-TheStreet Upgrades Enanta Pharmaceuticals (ENTA) to B-
www.americanbankingnews.com - December 15 at 7:48 PM
Enanta Pharmaceuticals, Inc.: Leads amongst peers with strong fundamentalsEnanta Pharmaceuticals, Inc.: Leads amongst peers with strong fundamentals
finance.yahoo.com - December 14 at 5:44 PM
ETFs with exposure to Enanta Pharmaceuticals, Inc. : December 14, 2017ETFs with exposure to Enanta Pharmaceuticals, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:44 PM
Zacks: Brokerages Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of $0.05 Per ShareZacks: Brokerages Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of $0.05 Per Share
www.americanbankingnews.com - December 14 at 1:16 AM
Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: 2017 By the Numbers : December 13, 2017Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: 2017 By the Numbers : December 13, 2017
finance.yahoo.com - December 13 at 5:22 PM
Enanta Pharmaceuticals Inc (ENTA) Files 10-K for the Fiscal Year Ended on September 30, 2017Enanta Pharmaceuticals Inc (ENTA) Files 10-K for the Fiscal Year Ended on September 30, 2017
finance.yahoo.com - December 11 at 5:23 PM
Enanta Pharmaceuticals Inc (ENTA) Receives Average Rating of "Buy" from AnalystsEnanta Pharmaceuticals Inc (ENTA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 8 at 11:48 AM
Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : December 7, 2017Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : December 7, 2017
finance.yahoo.com - December 7 at 9:56 AM
 Analysts Expect Enanta Pharmaceuticals Inc (ENTA) Will Announce Quarterly Sales of $27.26 Million Analysts Expect Enanta Pharmaceuticals Inc (ENTA) Will Announce Quarterly Sales of $27.26 Million
www.americanbankingnews.com - November 28 at 2:42 PM
Zacks: Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.05 EPSZacks: Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.05 EPS
www.americanbankingnews.com - November 26 at 3:48 AM
Enanta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ENTA) : November 24, 2017Enanta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ENTA) : November 24, 2017
finance.yahoo.com - November 24 at 4:17 PM
Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : November 22, 2017Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : November 22, 2017
finance.yahoo.com - November 22 at 3:33 PM
Enanta Pharmaceuticals, Inc. to Host Earnings CallEnanta Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 21 at 6:31 PM
ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 21, 2017ETFs with exposure to Enanta Pharmaceuticals, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 6:31 PM
Enanta Pharmaceuticals, Inc. (ENTA) Announces Quarterly  Earnings ResultsEnanta Pharmaceuticals, Inc. (ENTA) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 21 at 7:43 AM
Royal Bank Of Canada Boosts Enanta Pharmaceuticals, Inc. (ENTA) Price Target to $58.00Royal Bank Of Canada Boosts Enanta Pharmaceuticals, Inc. (ENTA) Price Target to $58.00
www.americanbankingnews.com - November 21 at 7:43 AM
Short Interest In Enanta Pharmaceuticals Moves 22.6% LowerShort Interest In Enanta Pharmaceuticals Moves 22.6% Lower
www.thestreet.com - November 21 at 5:09 AM
Edited Transcript of ENTA earnings conference call or presentation 20-Nov-17 9:30pm GMTEdited Transcript of ENTA earnings conference call or presentation 20-Nov-17 9:30pm GMT
finance.yahoo.com - November 21 at 5:09 AM
Enanta Pharmaceuticals posts 4Q profitEnanta Pharmaceuticals posts 4Q profit
finance.yahoo.com - November 20 at 7:06 PM
Enanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of "Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 13 at 12:34 PM
Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2017Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2017
finance.yahoo.com - November 13 at 11:33 AM
Enanta Pharmaceuticals, Inc. (ENTA) to Release Earnings on MondayEnanta Pharmaceuticals, Inc. (ENTA) to Release Earnings on Monday
www.americanbankingnews.com - November 13 at 2:08 AM
Enanta Pharmaceuticals Ranked As One Of North Americas Fastest Growing Companies On Deloittes 2017 Technology Fast 500™Enanta Pharmaceuticals Ranked As One Of North America's Fastest Growing Companies On Deloitte's 2017 Technology Fast 500™
www.thestreet.com - November 11 at 1:00 PM
Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™Enanta Pharmaceuticals Ranked as One of North America’s Fastest Growing Companies on Deloitte’s 2017 Technology Fast 500™
finance.yahoo.com - November 10 at 12:53 PM
Zacks: Brokerages Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Announce Quarterly Sales of $72.75 MillionZacks: Brokerages Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Announce Quarterly Sales of $72.75 Million
www.americanbankingnews.com - November 9 at 10:48 AM

SEC Filings

Enanta Pharmaceuticals (NASDAQ:ENTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Enanta Pharmaceuticals (NASDAQ:ENTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enanta Pharmaceuticals (NASDAQ ENTA) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.